UroGen Pharma Ltd. Foreign Currency Transaction Gain (Loss), before Tax
UroGen Pharma Ltd. (URGN) reported Foreign Currency Transaction Gain (Loss), before Tax of -$1.00 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2019-11-12
- UroGen Pharma Ltd. foreign currency transaction gain (loss), before tax for the quarter ending 2018-09-30 was $0.00.
- UroGen Pharma Ltd. foreign currency transaction gain (loss), before tax for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. foreign currency transaction gain (loss), before tax for the quarter ending 2018-03-31 was -$1.00K, a 200.00% decline year-over-year.
- UroGen Pharma Ltd. foreign currency transaction gain (loss), before tax for the quarter ending 2017-12-31 was $1.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | -$1.00K 10-Q · filed 2019-11-12 | $0.00 derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$1.00K 10-Q · filed 2019-08-09 | $0.00 derived: sum of 3 quarters · filed 2019-08-09 | $0.00 derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | -$1.00K 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-05-09 | $0.00 derived: sum of 3 quarters · filed 2019-05-09 | $1.00K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $1.00K derived: 20-F 12 month − 6-K 9 month · filed 2018-03-15 | $1.00K derived: sum of 2 quarters · filed 2018-11-13 | $2.00K derived: sum of 3 quarters · filed 2018-11-13 | $3.00K 20-F · filed 2018-03-15 |
| 2017-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | $1.00K derived: sum of 2 quarters · filed 2018-11-13 | $2.00K 6-K · filed 2018-11-13 | |
| 2017-06-30 | $1.00K derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | $2.00K 6-K · filed 2018-08-14 | ||
| 2017-03-31 | $1.00K 6-K · filed 2018-05-15 | |||
| 2015-12-31 | $1.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |